Coronaviruses first garnered widespread attention in 2002 when the severe acute
respiratory syndrome coronavirus (SARS-CoV) emerged from bats in China and rapidly
spread in human populations. Since then, Middle East respiratory syndrome coronavirus
(MERS-CoV) emerged and still actively infects humans. The recent SARS-CoV-2 outbreak and
the resulting disease (coronavirus disease 2019, COVID19) have rapidly and
catastrophically spread and highlighted significant limitations to our ability to
control and treat infection. Thus, a basic understanding of entry and replication
mechanisms of coronaviruses is necessary to rationally evaluate potential antivirals.
Here, we show that polyamines, small metabolites synthesized in human cells, facilitate
coronavirus replication and the depletion of polyamines with FDA-approved molecules
significantly reduces coronavirus replication. We find that diverse coronaviruses,
including endemic and epidemic coronaviruses, exhibit reduced attachment and entry into
polyamine-depleted cells. We further demonstrate that several molecules targeting the
polyamine biosynthetic pathway are antiviral
in vitro
. In sum, our data
suggest that polyamines are critical to coronavirus replication and represent a highly
promising drug target in the current and any future coronavirus outbreaks.